New AMD drug enters trials

Article

iSONEP (sonepcizumab), Lpath, Inc's drug candidate for treating age-related macular degeneration (AMD), has been administered to the first patients in its Phase I trial.

iSONEP (sonepcizumab), Lpath, Inc.'s drug candidate for treating age-related macular degeneration (AMD), has been administered to the first patients in its Phase I trial.

Unlike other AMD treatments, iSONEP, an antibody, targets not vascular endothelial growth factor (VEGF) but sphingosine-1-phosphate (S1P), a bioactive lipid that promotes angiogenesis, inflammation, cell survival and cell proliferation.

Lpath believes that, unlike anti-VEGF drugs, a treatment targeting the S1P pathway would arrest disease progression by reducing inflammation and mitigating fibrosis in addition to its anti-angiogenic properties. Although this hypothesis has been validated in animal trials, there are currently no S1P antibody therapies available for human use.

Lpath hopes that iSONEP will prove a viable candidate, either alone or as an adjunct to anti-VEGF treatments, for AMD as well as potentially having application in other fibrosis, angiogenesis or inflammation disorders.

Recent Videos
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
Abdelrahman Elhusseiny, MD, MSc, discusses his AAO presentation on risk of posterior capsular rupture in fellow-eyes cataract surgery
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Related Content
© 2024 MJH Life Sciences

All rights reserved.